Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Acyclic nitrogen double bonded to acyclic nitrogen – acyclic...
Patent
1994-01-07
1996-03-12
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Acyclic nitrogen double bonded to acyclic nitrogen, acyclic...
514166, A61K 31655, A61K 31615
Patent
active
054986087
ABSTRACT:
The present invention provides a method of colon cancer chemoprevention or chemotherapy comprising administering to an individual suffering from colon cancer or at risk to develop colon cancer a pharmaceutical composition comprising an effective amount of a 2-hydroxy-5-phenylazobenzoic acid derivative or an ester of an active metabolite thereof, or a pharmacologically acceptable salt of the 2-hydroxy-5-phenylazobenzoic acid derivative or an ester or an active metabolite thereof.
REFERENCES:
patent: 4412992 (1983-11-01), Chan
Stedman's Medical Dictionary, 24th Ed, Williams & Wilkins, Balto, MO, (1983), p. 297.
Bickel et al., "Gastric gel mucus thickness: Effect of distention, 16,16-dimethyl prostaglandin E.sub.2 and carbenoxolone" Gastroenterology (1981) 80:770-775.
Miller, "Protective effects of prostaglandins against gastric mucosal damage: Current knowledge and proposed mechanisms" Am. J. Physiol. (1983) 245(Gastrointest. Liver Physiol. 8):G601-G623.
Bukhave et al., "Saturation kinetics applied to in vitro effects of low prostaglandin E.sub.2 and F.sub.2a concentrations on ion transport across human jejunal mucosa" Gastroenterology (1980) 78:32-42.
Konturek et al., "Epidermal growth factor (EGF) and gastric cytoprotection. Role of endogenous prostaglandins (PGs) and DNA synthesis" Gastroenterology (1981) 80:1196.
Konturek et al., "Comparison of atropine and pirenzepine on gastric acid and serum hormonal responses to sham-feeding and gastric distention in duodenal ulcer (DU) patients" Gastroenterology (1981) 80:1196.
Konturek et al., "Generation of prostaglandins (PGs) in gastrointestinal mucosa of healthy subjects and duodenal ulcer (DU) patients" Gastroenterology (1981) 80:1196.
Konturek et al., "Ranitidine (R), a new potent H.sub.2 -receptor antagonist. Comparison with cimetidine (C) on gastric and pancreatic secretion in duodenal ulcer (DU) patients" Gastroenterology (1981) 80:1196.
Whittle et al., "Prostanoids as regulators of gastrointestinal function" Physiology of the Gastrointestinal Tract, Johnson, L. R., ed., (1987) 2nd Edition, Raven Press, New York, Chapter 6, pp. 143-180.
Kitahora et al., "Active oxygen species generated by monocytes and polymorphonuclear cells in Crohn's disease" Dig. Dis. Sci. (1988) 33:951-955.
Tauber et al., "Neutrophil oxygen reduction: The enzymes and the products" Adv. Free Radical Biol. Med. (1985) 1:265-307.
Ohlsson et al., "Localization of chymotrypsin-like cationic protein, collagenase and elastase in azurophil granules of human neutrophilic polymorphonuclear leukocytes" Hoppe-Seylers Z. Physiol. Chem. (1977) 358:361-366.
Lennard-Jones et al., "Cancer in colitis: Assessment of the individual risk by clinical and histological criteria" Gastroenterology (1977) 73:1280-1289.
Farmer et al., "Carcinoma associated with mucosal ulcerative colitis, and with transmural colitis and enteritis (Crohn's Disease)" Cancer (1971) 28:289-292.
Sipponen et al., "Atrophic chronic gastritis and intestinal metaplasia in gastric carcinoma" Cancer (1983) 52:1062-1067.
Reddy et al., "Metabolic epidemiology of large bowel cancer" Mutation Res. (1980) 72:511-522.
Armstrong et al., "Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices" Int. J. Cancer (1975) 15:617-631.
Grisham, "Effect of 5-aminosalicylic acid on ferrous sulfate-mediated damage to deoxyribose" Biochem. Pharmacol. (1990) 39:2060-2063.
Mukai et al., "Mutagenicity of malonaldehyde, a decomposition product of perixodized polyunsaturated fatty acids" Science (1976) 191:868-869.
Basu et al., "Unequivocal demonstration that malondialdehyde is a mutagen" Carcinogenesis (1983) 4:331-333.
Basu et al., "Dissociation of malondialdehyde mutagenicity in Salmonella typhimurium from its ability to induce interstrand DNA cross-links" Mutation Res. (1984) 129:36-46.
Marnett, "Polycyclic aromatic hydrocarbon oxidation during prostaglandin biosynthesis" Life Sci. (1981) 29:531-546.
Adams et al., "The cell biology of macrophage activation" Ann. Rev. Immunol. (1984) 2:283-318.
Nathan et al., "Cellular component of inflammation: Monocytes and macrophages" Textbook of Rheumatology Kelley, W. N., et al., eds., W. B. Saunders Company, Philadelphia, (1981) Chapter 6, pp. 136-162.
Seilhamer et al., "Cloning and recombinant expression of phospholipase A.sub.2 present in rheumatoid arthritic synovial fluid" J. Biol. Chem. (1989) 264:5335-5338.
Minami et al., "Raised serum activity of phospholipase A.sub.2 immunochemically related to group II enzyme in inflammatory bowel disease: Its correlation with disease activity of Crohn's disease and ulcerative colitis" Gut (1992) 33:914-921.
Wright et al., "Purification of a cellular (granulocyte) and an extracellular (serum) phospholipase A.sub.2 that participate in the destruction of Escherichia coli in a rabbit inflammatory exudate" J. Biol. Chem. (1990) 265:6675-6681.
Hayakawa et al., "The primary structure of rat platelet phospholipase A.sub.2 " J. Biochem. (1988) 104:767-772.
Lyons-Giordano et al., "Interleukin-1.beta. stimulates phospholipase A.sub.2 mRNA synthesis in rabbit articular chondrocytes" Biochem. Biophys. Res. Commun. (1989) 164:488-495.
Nakano et al., "Group II phospholipase A.sub.2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells" FEBS Lett. (1990) 261:171-174.
Pfeilschifter et al. "Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells" Biochem. Biophys. Res. Commun. (1989) 159:385-394.
Oka et al., "Inflammatory factors stimulate expression of group II phospholipase A.sub.2 in rat cultured astrocytes" J. Biol. Chem. (1991) 266:9956-9960.
Okada et al., "Generation of cytotoxic lipid substance in cell-mediated cytotoxicity" Japan. J. Exp. Med. (1975) 45:533-534.
Kristensen et al., "Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract" J. Cell Biol. (1991) 115:1763-1771.
Lund et al., "Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells" J. Biol. Chem. (1991) 266:5177-5181.
Lund et al., "Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor .beta.1 in human A549 lung carcinoma cells" EMBO J. (1991) 10:3399-3407.
Stoppelli et al., "Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes" Natl. Acad. Sci. USA (1985) 82:4939-4943.
Pyke et al., "Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas" Am. J. Pathol. (1991) 138:1059-1067.
Ossowski et al., "In vivo paracrine interaction between urokinase and its receptor: Effect on tumor cell invasion" J. Cell. Biol. (1991) 115:1107-1112.
Narisawa et al., "Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment" Cancer Res. (1981) 41:1954-1957.
Pollard et al., "The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat" Cancer Lett. (1983) 21:57-61.
Moorghen et al., "A protective effect of sulindac against chemically-induced primary colonic tumours in mice" J. Pathol. (1988) 156:341-347.
Reddy et al., "Aspirin inhibits cancer of the colon" Gastroenterology (1993) 104:A443.
Kune et al., "Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne colorectal cancer study" Cancer Res. (1988) 48:4399-4404.
Paganini-Hill et al., "Aspirin use and incidence of large-bowel cancer in a California retirement community" J. Natl. Cancer Inst. (1991) 83:1182-1183.
Labayle et al., "Sulindac causes regression of rectal polyps in familial adenomatous polyposis" Gastroenterology (1991) 101:635-639.
Klein et al., "The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with fa
Johnson Lorin K.
Sleisenger Marvin H.
Goldberg Jerome D.
Salix Pharmaceuticals
LandOfFree
Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon ca does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon ca, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon ca will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2100072